REDWOOD CITY, Calif., May 31, 2023 (GLOBE NEWSWIRE) — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the appointments of Paul E. Cayer as Chief Financial Officer and Omega Therapeutics…Read More
Ashvattha Therapeutics Expands Leadership Team with Appointment of Paul E Cayer as Chief Financial Officer and Mahesh Karande to the Board of Directors Omega Therapeutics NASDAQOMGA
